Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: W.D, H.Z., X.W., F.P., R.D., and B.G. are employed by Moderna Inc. and have stock or stock options in Moderna Inc. H.E.J. serves/served as an unpaid member within the past 36 months as a DSMB member for a Phase II monkeypox vaccine study (DMID) and for a Phase I oral cholera vaccine study (DMID). M.C. reports an honorarium for service within the past 36 months on a grant review panel for the National Comprehensive Cancer Network and Pfizer. C.J.F. reports grants to his institution within the past 36 months from Gilead Sciences, ViiV Healthcare, and Merck, as well as payment for advisory board participation within the past 36 months from ViiV Healthcare and Theratechnologies, Inc. K.M.N. reports grants to her institution within the past 36 months from Pfizer to conduct clinical trials of COVID-19 vaccines, but K.M.N. receives no salary support from these grants. K.M.N. reports a grant from Vaxco within the past 36 months for phase 1 testing of a broadly reactive COVID-19 vaccine. F.P. was a member of the CEPI Scientific Advisory Board within the past 36 months and reports support from Moderna, Inc. for attending meetings and/or travel within the past 36 months. Within the past 36 months, L.R.B. was involved in HIV and SARS-CoV-2 vaccine clinical trials conducted in collaboration with the NIH, HIV Vaccine Trials Network (HVTN), Covid Vaccine Prevention Network (CoVPN), International AIDS Vaccine Initiative (IAVI), Crucell/Janssen, Moderna, Military HIV Research Program (MHRP), the Gates Foundation, and Harvard Medical School; as well as participated on a DSMB for the NIH and an AMDAC Committee for the FDA. P.B.G. served as an unpaid member of the Moderna Zika Vaccine Scientific Advisory Board within the past 36 months. All authors declare no other support from any commercial entity for the submitted work; no other financial relationships with any commercial entities that might have an interest in the submitted work in the past 36 months, and no other relationships or activities within the past 36 months that could appear to have influenced the submitted work.

Funding Statement

Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority Contracts No. 75A50120C00034 (P3001 study) and No. 75A50122C00013 (Immune Assays). National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant R37AI054165 (PBG). National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant UM1AI068635 (PBG). National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant AI068614 (LC). National Cancer Institute, National Institutes of Health, Contract No. 75N91019D00024. National Institute of Allergy and Infectious Diseases of the National Institutes of Health grant 3UM1AI148575 (Baylor College of Medicine VTEU). The findings and conclusions herein are those of the authors and do not necessarily represent the views of the Department of Health and Human Services or its components. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The mRNA-1273-P301 study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice guidelines, and applicable government regulations. The Central Institutional Review Board approved the mRNA-1273-P301 protocol and the consent forms. All participants provided written informed consent before enrollment. Central IRB services for the mRNA-1273-P301 study were provided by Advarra, Inc., 6100 Merriweather Dr., Suite 600, Columbia, MD 21044. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes